Related Experiment Videos
Natural history of chronic hepatitis C
1Institute for Clinical Research, Nagasaki Chuo National Hospital, WHO Collaborating Center for Reference and Research on Viral Hepatitis, Japan. yatsuhashi@nmc.hosp.go.jp
Insights
Hepatitis C progresses slowly, often leading to liver cancer (HCC). Advanced fibrosis and age over 50 significantly increase HCC risk in chronic hepatitis C patients.
Area of Science:
- Hepatology
- Oncology
- Viral Hepatitis Research
Background:
- Chronic hepatitis C (CHC) naturally progresses from early stages to cirrhosis or hepatocellular carcinoma (HCC).
- Mortality in CHC is primarily linked to HCC development, particularly in regions like Japan.
- Understanding CHC progression and identifying HCC risk factors is crucial for patient management.
Purpose of the Study:
- To investigate the natural history of chronic hepatitis C and identify predictors of hepatocellular carcinoma (HCC) development.
- To assess the cumulative probability of HCC development over time in a cohort of Japanese patients.
- To determine independent risk factors for HCC in patients with CHC.
Main Methods:
- Retrospective analysis of 186 patients with CHC referred between 1968 and 1994.
- Mean follow-up duration of 8.6 years, with a range of 2-23 years.
- Univariable and multivariable analyses to identify predictive risk factors for HCC, including age, fibrosis stage, inflammation, and IFN treatment.
Main Results:
- Hepatocellular carcinoma (HCC) developed in 18% (34/186) of patients.
- Cumulative HCC probability reached 4% at 5 years, 18% at 10 years, and 45% at 15 years.
- Independent predictors for HCC were age at entry (>50 years) and advanced fibrosis stage (F3).
Conclusions:
- Approximately 20% of CHC patients in Japanese liver clinics may develop HCC within 10 years.
- The risk of HCC escalates with advancing liver fibrosis (F3-F4) and patient age (>50 years).
- Liver fibrosis stage is a critical determinant for predicting HCC occurrence in chronic hepatitis C.
Abstract:
The natural history of chronic hepatitis C is one of a slow progression from early stage chronic hepatitis without fibrosis to cirrhosis or hepatocellular carcinoma (HCC). The disease progresses to advanced stage chronic hepatitis C over 10-30 years. Data from Japan indicate that mortality associated with chronic hepatitis C results mainly from the development of HCC. We studied 186 patients referred between 1968 and 1994. The mean follow-up interval was 8.6 (2-23) years. HCC developed in 34 patients (18%). The cumulative probability of HCC development was 4% at 5 years, 18% at 10 years and 45% at 15 years. Univariable analysis indicated that age at entry, fibrosis stage, inflammation activity and the status of IFN treatment (treated vs untreated) were predictive risk factors for developing HCC in patients with chronic hepatitis C. Multivariable analysis of these risk factors indicated that age at entry (> 50 vs < 50; Risk Ratio = 3.2, P< 0.005) and fibrosis stage (F3 vs F0; Risk Ratio= 5.6, P< 0.005) are independent risk factors for HCC. From these results it was concluded that (1) 20% of patients referred to liver clinics with chronic hepatitis C in Japan can be expected to develop HCC over a 10 year period; (2) the risk of HCC increases with progression of liver fibrosis (F3, F4) and age (greater than 50 years old) at the time of diagnosis and (3) the degree of liver fibrosis is a critical predictive factor for the occurrence of HCC.